Infectious complications associated with immunomodulating biologic agents.
The armamentarium of biologic therapies targeting specific elements of the immune system is rapidly expanding. This review describes the spectrum of infectious complications associated to date with each of the immunomodulating biologic therapies approved by the US Food and Drug Administration.
Koo
Sophia
S
Division of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, PBB-A4, Boston, MA 02115, USA. skoo@partners.org
Marty
Francisco M
FM
Baden
Lindsey R
LR
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000453:epidemiology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use*; D014481:United States
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors